Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - Monopar Therapeutics Inc. has announced a registered offering of common stock and pre-funded warrants, aiming to raise approximately $100 million for general corporate purposes, including research and development [1][2][3]. Group 1: Offering Details - The offering consists of 1,034,433 shares of common stock priced at $67.67 per share and pre-funded warrants to purchase 960,542 shares at $67.669 each [1]. - The gross proceeds from the offering, net of anticipated stock repurchase, are expected to be around $100 million before underwriting discounts and expenses [2]. - The offering is anticipated to close on or about September 25, 2025, subject to customary closing conditions [3]. Group 2: Use of Proceeds - Monopar plans to allocate up to $35 million of the proceeds to repurchase shares from Tactic Pharma, LLC at a price of $63.6098 per share, which is equivalent to the offering price for investors [3]. Group 3: Management and Registration - Morgan Stanley, Leerink Partners, and Barclays are serving as lead book-running managers for the offering [4]. - The securities are being offered under a "shelf" registration statement filed with the SEC, with a prospectus supplement to be made available [5]. Group 4: Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments, including late-stage ALXN1840 for Wilson disease and various radiopharmaceutical programs for advanced cancers [7].